DataLabs Announces Launch of Site Manager 2.0, an Advanced CT Management Portal Including Digital Signature Technology
DataLabs is the first vendor to implement electronic signatures out-of-the-box guaranteeing signer authenticity and data integrity.
PHILADELPHIA-June 19, 2006-DataLabs, an innovative developer of Internet-based software applications for clinical development, today announced the launch of Site Manager™ 2.0 at the 42nd Annual Drug Information Association (DIA) Meeting. Advanced clinical trial software, Site Manager 2.0 improves the site selection and activation processes as well as overall site satisfaction with easy to use, Web-based site management software. Site Manager 2.0 integrates CoSign®, Algorithmic Research's (ARX's) electronic signature solution, enabling users to sign documents with secure, regulatory compliant, electronic signatures that complete the migration to paperless processes, further streamlining clinical trial efficiency.
Site Manager 2.0 is a communication portal that extends electronic data capture, allowing sponsors, clinical research organizations (CROs), investigator sites and other trial participants to streamline data exchange and entry, document processing and data management. With Site Manager 2.0, sponsors or CROs can quickly identify and initiate investigator sites and then monitor and administer the site during the course of the trial. Built on Microsoft's SharePoint technology, Site Manager 2.0 meets CDISC ODM standards and complies with FDA 21 CFR Part 11.
DataLabs will be at booth #1829 at the DIA Annual Conference.
Articles in this issue
over 19 years ago
Article
Phase Forward Delivers Enhanced Integration Capabilities as Part of Ongoing Adapter Strategyover 19 years ago
Article
ClinPhone Exhibits its Clinical Trial Technology Solutions at 42nd DIA Annual Meetingover 19 years ago
Article
Omnicomm Systems Inc., Introduces New TrialMaster V.4.0 at DIA's 42nd Annual MeetingNewsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- Everything to Know About FDA’s Push Towards Radical Transparency in 2025
September 17th 2025
- IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes
September 17th 2025
- Managing Background Therapies in the NIMBLE Phase III Trial
September 17th 2025
- Generative AI Transforms Clinical Study Report Development
September 16th 2025